Oncology
1 drug is in development for Myasthenia Gravis.
- Companies
- 1
- Clinical trials
- 22
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Myasthenia Gravis pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| anito-cel | Arcellx, Inc. (ACLX) |
About this indication
Myasthenia Gravis context
Oncology·MeSH: Myasthenia Gravis (D009157)
Narrower concepts tracked separately: Myasthenia Gravis, Generalized, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG)
Incidence
1.7 / 100K/yr
Frequently asked questions
How many drugs are in development for Myasthenia Gravis?
BioSniper tracks 1 drug in development for Myasthenia Gravis across 1 company.
How many clinical trials target Myasthenia Gravis?
There are 22 clinical trials targeting Myasthenia Gravis tracked by BioSniper.